Sales SEK 17.9m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -0.
Redeye retains its positive view of Hexatronic following a solid Q2 2023 but with soft guidance for ...
Redeye comments on EG7’s Q2-results which was in line with expectations where performance in the Gam...
En optimerad försäljningsmix resulterade i en rekordhög nettovinst för kvartalet och vi prognostiser...
We cut '24e-'25e sales by 32-8% due to the Ovzon-3 delay We now expect Ovzon-3 to generate sales as ...
Q2: EBITDA PLN 69m vs. ABGSCe of PLN 112m Paper market balance under pressure from weak demand Fair ...
Redeye updates its fair value range following FlexQube’s share issue announcement, where it aims to ...
Redeye reiterates its fair value range following a solid Q2’23 report that presented surprisingly so...
Redeye is mostly positive to today’s news that Saniona has renegotiated its loan from Formue Nord.
As a part of its cost-saving program, DT today initiated change negotiations which may end up in a t...
Tumorad i skarpt läge Efter år av utvecklingsarbete har det blivit dags att inleda utvärdering av Tu...
Carlsquare Equity Research sammanfattar sina första intryck av Spotlight Groups kv2-rapport.
We lower '23e-'25e sales by 5-8%Algo rebound as early as H2'23'23e-'24e EV/EBITDA of 27x-5x What to ...
Redeye comments on the inclusion of the last patient in the Lenvima arm of the phase IIa trial of fo...
Marimekko publishes its Q2 result on Thursday, Aug 17th.
Redeye initiates coverage of Ortoma, a Swedish medtech company in early stage commercialisation with...
Redeye retains its positive view of Efecte following the Q2 report.
Redeye provides a brief update on BeammWaves, after its Q2’23 report.
Redeye comments on today’s news that Annexin has seen initial signals of effect in the ongoing phase...
Negativ organisk tillväxt och marginalpress… Med accelererande avveckling av kopparnäten såg Sverige...
